Gabriella Miller Kids First Research Act 2.0

Gabriella Miller Kids First Research Act 2.0

This bill reauthorizes through FY2027 a pediatric disease research initiative within the National Institutes of Health (NIH) and requires the NIH to coordinate pediatric research activities to avoid duplicative efforts. Additionally, the Department of Health and Human Services must report, within five years, to Congress about research funded through the initiative.

Bill 117 HR 623, also known as the Gabriella Miller Kids First Research Act 2.0, is a piece of legislation that aims to support pediatric medical research. The bill builds upon the original Gabriella Miller Kids First Research Act, which was passed in 2014.

The main goal of the Gabriella Miller Kids First Research Act 2.0 is to allocate funding for research into childhood diseases and disorders. This funding will come from penalties collected from pharmaceutical companies that have been found to engage in fraudulent practices. The bill specifically targets companies that have been found guilty of defrauding the government in relation to Medicaid or Medicare.

The funds collected from these penalties will be directed towards the National Institutes of Health (NIH) for the purpose of conducting research on pediatric diseases. This research will focus on finding cures and treatments for conditions that affect children, such as cancer, autism, and rare genetic disorders. Overall, the Gabriella Miller Kids First Research Act 2.0 aims to prioritize the health and well-being of children by investing in research that can lead to breakthroughs in pediatric medicine. By using penalties from fraudulent pharmaceutical companies to fund this research, the bill ensures that those who have harmed the healthcare system will contribute to efforts to improve it.